Valuation: Myriad Genetics, Inc.

Market Cap 384M 334M 315M 287M 538M 36.75B 538M 3.77B 1.45B 18.72B 1.44B 1.41B 60.4B P/E 2026 *
-2.52x
P/E 2027 * -3.2x
Enterprise Value 335M 292M 275M 250M 469M 32.05B 470M 3.29B 1.27B 16.33B 1.26B 1.23B 52.69B EV / Sales 2026 *
0.43x
EV / Sales 2027 * 0.38x
Free-Float
96.04%
Yield 2026 *
-
Yield 2027 * -
1 day+3.08%
1 week+5.80%
Current month+24.53%
1 month+25.31%
3 months-11.67%
6 months-12.45%
Current year-34.80%
1 week 3.75
Extreme 3.75
4.17
1 month 2.92
Extreme 2.92
4.17
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
35.31
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Free

Executive/Senior Manager

257,731 0.2695%
9/16/26 Other

Executive/Senior Manager

93,493 0.0977%
9/16/26 Other

Executive/Senior Manager

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+3.08%+5.80%-48.39%-76.09% 372M
-3.07%+3.59%+193.95%+565.91% 24.07B
+3.26%+12.82%+506.60%+88.74% 9.98B
+0.98%+1.05%-36.47%-19.81% 9.66B
+2.23%+17.66%-5.92% - 8.47B
-0.27%-0.04%+98.93%+66.38% 6.56B
+0.22%+1.05%-27.93%-21.41% 5.74B
+1.77%+5.52%-0.86%-10.66% 4.35B
+2.67%+7.74%+65.15%+70.58% 3.89B
+1.09%+2.49%-19.18%-29.97% 2.74B
Average +1.20%+6.61%+72.59%+70.41% 7.58B
Weighted average by Cap. +0.11%+9.02%+131.72%+218.90%

Financials

2026 *2027 *
Net sales 778M 678M 639M 582M 1.09B 74.52B 1.09B 7.65B 2.95B 37.96B 2.92B 2.86B 122B 821M 716M 674M 614M 1.15B 78.67B 1.15B 8.08B 3.11B 40.07B 3.08B 3.02B 129B
Net income -143M -125M -118M -107M -201M -13.73B -201M -1.41B -543M -6.99B -538M -526M -22.57B -106M -92.52M -87.14M -79.36M -149M -10.17B -149M -1.04B -402M -5.18B -399M -390M -16.71B
Net Debt -49M -42.72M -40.24M -36.64M -68.7M -4.69B -68.79M -482M -186M -2.39B -184M -180M -7.72B -74.14M -64.64M -60.88M -55.45M -104M -7.1B -104M -729M -281M -3.62B -278M -272M -11.68B
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-09-21 $4.010 +3.08% 1,890,087
26-09-18 $3.890 -6.04% 3,509,964
26-09-17 $4.140 +7.25% 2,830,839
26-09-16 $3.860 -0.52% 2,049,663
26-09-15 $3.880 +2.37% 4,680,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
4.010USD
Average target price
3.367USD
Spread / Average Target
-16.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!